• Cathy Yen

    Chairman of the Board

    Ms. Cathy Yen is chairman of the board at Sundia Meditech Group, where she acts as the key architect of Sundia’s strategic vision and growth. Under her leadership, Sundia has solidified its position as one of the leading pre-clinical CROs in China. Prior to Sundia, Ms. Yen had a distinguished career as a seasoned venture capitalist, having led numerous investments in high-growth companies in Asia. Ms. Yen served as a Partner of AsiaVest Partners, TCW/YFY Ltd., a global venture capital firm, for over a decade, Vice President at Global Financial Services (a JV with Lehman Brothers in Taiwan), Vice President at Crimson Ventures/Chinatrust Bank and Senior Manager at Fortune Capital. She brings over 20 years of experience in corporate finance, accounting, strategic planning and private equity investments.

  • Wilma Wei

    Independent director

    Ms. Wilma Wei has served as an independent director of the company since August 2012. Ms. Wei is currently Senior Vice President at Compal Electronics, a leading global manufacturer of notebook PCs, display products and smart devices. Ms. Wei has extensive experience in finance and accounting as well as corporate development. She has also served on the board of directors of a number of private and publicly listed companies in the areas of technology, telecom and healthcare.

    Ms. Wei is currently chair of the company’s audit committee.

  • Karen Tzu-Ling Tseng, Ph.D.

    Independent Director

    Dr. Karen Tseng has served as an independent director of the company since June 2015. She is currently Chairman and CEO of Bio Preventive Medicine Corp., a leading clinical stage biotech company in Taiwan. Dr. Tseng has over 20 years of diverse research experiences in basic and applied biomedical science in Taiwan and the U.S. After receiving her doctorate degree in genetics, Dr. Tseng joined the National Cancer Institute, NIH in Bethesda, Maryland, where she began working with biomarker development. She subsequently joined the Industrial Technology Research Institute (ITRI) in Taiwan where she initiated and led the biomarker program. Throughout her distinguished career, Dr. Tseng received numerous awards for her research, including the NIH Fellows Award for Research Excellence in Genetics-Human, ITRI Best Innovation Award and National Industrial Innovation Award: Woman Innovator Award.

  • Henry Shaw


    Mr. Henry Shaw has served as director of the company since June 2017. Mr. Shaw has extensive technology investment experience and a deep network in Greater China. He was formerly a Senior Partner of AsiaVest Partners, TCW/YFY Ltd., a global venture capital firm, director of Semiconductor International Manufacturing Corporation as well as CFO and Head of Operations at Mosel Vitelic, Inc., a leading DRAM manufacturer in Taiwan.

  • Bernice Huang


    Ms. Bernice Huang has served as director of the company since June 2017. Ms. Huang is currently an Executive Director at AsiaVest Capital. Prior to AsiaVest, Ms. Huang was the special assistant to the CEO of Egis Technology, Inc., a leading IC design house focused on capacitive fingerprint sensors. Ms. Huang also has experience in leveraged finance and equity research, having worked as an Associate at Barclays Capital and as a research analyst at Goldman Sachs (Asia) L.L.C. in Hong Kong and Taiwan.

  • Patrick Zhang

    Representative of Treasure Tower Limited

    Mr. Patrick Zhang is a representative of Treasure Tower Limited, which is a corporate director of the company. Mr. Zhang is currently an executive director at IDG Capital with a focus on portfolio management in China.

  • Joseph W.F. Cheng


    Mr. Joseph W.F. Cheng has served as director of the company since October 2014. Mr. Cheng is currently Chairman of BoardTek Electronics, a leading manufacturer of printed circuit boards listed in Taiwan. Mr. Cheng possesses over 30 years of experience in management, operations and R&D in the technology sector.

  • Vincent Wang


    Mr. Vincent Wang has served as director of the company since June 2015. He has over 15 years of experience in venture capital investment and founding startups. He is the board director of Taiwan Venture Capital Association (TVCA) and an adjunct professor at National Taiwan University. Mr. Wang also serves on the boards of Taiwan Sugar Corporation (1237 TT), Solomon Technology Corporation (2359 TT), Sunder Biomedical Tech. Co., Ltd. (4115 TT), Uni-President Securities Investment Trust Co. and several other private and publicly listed companies. Vincent earned his Bachelor’s Degree in Electrical Engineering from National Taiwan University and MBA degree with a dual major in Finance & Entrepreneurial Management from the Wharton School of the University of Pennsylvania. Mr. Wang is also the charter holder of Certified Securities Investment Analyst (CSIA) in Taiwan.